Your Health, We Care
Release date: 2024-07-09 16:03:11 Recommended: 87
Koselugo, as a novel oral, potent, and selective MEK1/2 inhibitor, is suitable for the treatment of pediatric patients aged 2 and above with neurological disorders. Koselugo was first approved by the US FDA for marketing in April 2020, becoming the world's first targeted drug for NF1.
At a grand pharmaceutical exhibition held recently in Dubai, Lucius Company of L···【more】
Recommended：207Release date: 2024-07-09
On October 18-19, 2023, Dr. Luís Meirinhos Soares, a microbiology expert appoint···【more】
Recommended：220Release date: 2024-07-09
On October 19, 2023, the World Health Organization (WHO) conducted a comprehensi···【more】
Recommended：192Release date: 2024-07-09
At present, the competition in all walks of life is very fierce, especially in t···【more】
Recommended：158Release date: 2024-07-09
Here are some key points about Lucius Pharmaceutical:Lucius Pharmaceuticals has ···【more】
Recommended：290Release date: 2024-07-09
From the Black Sea, the most terrifying ocean on earth, to the Mediterranean Sea···【more】
Recommended：170Release date: 2024-07-09
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently mad···【more】
Recommended：326Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest incr···【more】
Recommended：196Release date: 2024-07-09
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) ···【more】
Recommended：154Release date: 2025-01-13
Recent advancements have reaffirmed the significance of liquid biopsy in the man···【more】
Recommended：151Release date: 2025-01-06
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Fo···【more】
Recommended：166Release date: 2024-12-30
The new indication involves the treatment of adult patients with locally advance···【more】
Recommended：157Release date: 2024-12-24
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont···【more】
Recommended：143Release date: 2024-12-17
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-C···【more】
Recommended：104Release date: 2024-12-13
